ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke
ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union's health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618236600/en/
The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry.
The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry.
The CE Mark approval is supported by a comprehensive body of evidence, including preclinical bench and animal studies, and clinical data from the recently published ANAIS study demonstrating high reperfusion and first-pass success rates. Further clinical validation is ongoing in the ATHENA trial, a prospective, multicenter randomized study systematically evaluating the impact of proximal flow arrest on reperfusion effectiveness, to support future regulatory submissions and commercialization efforts in the United States.
' Receiving CE Mark approval is a pivotal achievement for ANACONDA Biomed thatadvances our mission to innovate in the interventional management of acute ischemic stroke,' said Trent Reutiman, chief executive officer. " This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application.'
Dr. Marc Ribo, the co-founder of Anaconda Biomed, added, " Receiving CE Mark approval for ANA5 is deeply meaningful, as it represents the culmination of years of research, iteration, and belief in an idea that began at the bench. This is more than a regulatory milestone; it's the moment where innovation becomes impact. We're now gearing up to capture real-world data by collecting more invaluable insight into how ANA5 performs across diverse stroke centers and clinical realities. '
About ANA Funnel Catheter
ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States.
About Anaconda Biomed
Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit https://anaconda.bio and follow the company on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250618236600/en/
CONTACT: MEDIA CONTACT:
Joe Duraes
Pazanga Health Communications
[email protected]
917-687-6419
KEYWORD: SPAIN EUROPE
INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH CLINICAL TRIALS CARDIOLOGY
SOURCE: Anaconda Biomed
Copyright Business Wire 2025.
PUB: 06/18/2025 07:05 AM/DISC: 06/18/2025 07:03 AM
http://www.businesswire.com/news/home/20250618236600/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Barcelona lock in presentation date for their new signing
According to an update from Mundo Deportivo, it has come to light that Marcus Rashford will officially be presented as the new Barcelona player on Wednesday, July 23. It must be noted that the Manchester United forward arrived in the city on Sunday night to begin his loan tenure with Barça. The loan deal is for one season, with a €30 million buy option included. His first few days in Catalonia will be packed with activities before he joins the team's trip to Asia for the pre-season later in the week. On Monday morning, which is today, Rashford will undergo his medical tests at the Ciutat Esportiva de Sant Joan Despi. Even though Barcelona and Manchester United have already finalised the terms of his loan, the club has decided to push the official presentation back by a day. Presentation delayed due to Flick's training schedule Rashford was originally expected to be presented on Tuesday. However, Barcelona manager Hansi Flick has scheduled a double training session for that day, forcing the club to move the event to Wednesday afternoon instead. After training for the third time with his new teammates on Wednesday morning, Rashford will head back to the Spotify Camp Nou offices later in the day. In the evening, he will officially sign his contract in the presence of club president Joan Laporta. Right after putting pen to paper, Rashford will make his first comments as a Barcelona player to the club's in-house media. An hour later, the 27-year-old forward will attend a press conference at the Barça store in Spotify Camp Nou. There, he will speak to the press for the first time since completing his move from Manchester United. Following this eventful start, Rashford will then travel with the squad on Thursday to Japan, where Barcelona will kick off their pre-season tour.
CNBC
6 minutes ago
- CNBC
CNBC Daily Open: The silver lining of positive earnings could be too blinding
Friday, Aug. 1 — the "hard deadline" of U.S. President Donald Trump's updated tariffs — is less than two weeks away. Investors, however, seem mostly unbothered thus far. For last week, while the Dow Jones Industrial Average dipped marginally, the S&P 500 and Nasdaq Composite rose 0.6% and 1.5%, respectively. Even a report that Trump wanted a minimum of 15%-20% tariffs on the European Union only dealt a minimal blow to markets, which mostly closed unchanged Friday. Although those figures are higher than the universal 10% baseline tariff Trump reportedly wanted — and which the EU is hoping to secure — they are still lower than the 30% Trump said he will impose on the bloc in his July 12 letter. An upbeat start to earnings season has alsohelped to quell tariff fears for now. Around 83% of the S&P 500 companies that have reported earnings have exceeded expectations, according to FactSet data. In particular, big banks such as JPMorgan Chase and Goldman Sachs, which serve as barometers for economic activity, had solid beats, boosting investor sentiment. Next in the spotlight are Big Tech earnings, which will be released in the weeks right before Aug. better than expected, they might dispel geopolitical jitters — or cause investors to dismiss trade fears too readily. In these stormy times, every silver lining has a dark cloud. Aug. 1 is a 'hard deadline' for new tariffs. U.S. Commerce Secretary Howard Lutnick said Sunday that the tariffs will take effect next month, but left open the possibility of continuing trade negotiations after the date. U.S. stock futures are little changed Sunday stateside. On Friday, the S&P 500 and Nasdaq Composite closed around the flatline. The Dow Jones Industrial Average, however, lost 0.32%. Asia-Pacific markets traded mixed Monday. China keeps its benchmark lending rates steady. On Monday, the People's Bank of China announced it was holding the 1-year loan prime rate at 3.0% and the 5-year LPR at 3.5%. After the move, the offshore yuan remained mostly flat. Huawei has evolved from a telecom giant to artificial intelligence leader. Despite — or precisely because of — restrictions imposed on the Chinese company by the U.S. in 2019, Huawei has achieved breakthroughs in its chips and appears to be Beijing's answer to Nvidia. [PRO] The beneficiary of a foldable phone from Apple. While the Cupertino-based company has yet to release a foldable — unlike its rivals such as South Korea's Samsung and China's Honor — buyers are already lining up for a potential major supplier. Singapore dollar exhibits safe-haven currency features. But it's no yen or Swiss franc — yet While the greenback remains the world's reserve currency of choice, the dollar index has fallen over 9% year to date. The outlook for the Japanese yen has been clouded by trade worries. Against such a backdrop, analysts suggest there could be an alternative safe-haven currency in the making: the Singapore dollar.
Bloomberg
6 minutes ago
- Bloomberg
Russia-Linked Refinery in India Seeks Early Payment After Curbs
A refinery in India that's part-owned by a Russian energy producer tightened conditions for selling products after the European Union imposed sanctions on the company, highlighting the fallout for the processor, its customers, and the wider market from the tougher restrictions. Nayara Energy Ltd., part-owned by Rosneft PJSC, said it was seeking advance payment or a documentary letter of credit, before loading a shipment of naphtha next month, according to a revised tender document seen by Bloomberg. An earlier tender asked for no such requirements.
